接受体外膜氧合的急性呼吸窘迫综合征患者死亡率预测模型的比较及新型预测评分PREdiction of Survival on ECMO Therapy-Score(PRESET-Score)的开发
该研究在108例接受静脉-静脉体外膜氧合(ECMO)的急性呼吸窘迫综合征(ARDS)患者(2010-2015年)中回顾性验证了四种已有风险评分(ECMOnet-Score、RESP-Score、PRESERVE-Score、Roch-Score)对死亡率的预测能力,并通过多变量logistic回归分析确定独立预测变量,构建了新的PRESET-Score。仅ECMOnet-Score(AUC 0.69)和RESP-Score(AUC 0.64)能区分存活者与死亡者。PRESET-Score基于入ICU时pHa、平均动脉压、乳酸、血小板计数和ECMO前住院时间构建,内部验证(n=82)AUC 0.845(95%CI 0.76-0.93,p<0.001),外部验证(n=59)AUC 0.70(95%CI 0.56-0.84,p=0.008)。作者认为PRESET-Score预测死亡率远优于既往评分,可能是ARDS患者ECMO置入决策支持的更精确选择。
要点
- 在108例静脉-静脉ECMO治疗的ARDS患者中,仅ECMOnet-Score(AUC 0.69)和RESP-Score(AUC 0.64)能区分存活者与死亡者。
- PRESET-Score由入ICU时pHa、平均动脉压、乳酸、血小板计数和ECMO前住院时间五个独立预测变量构成。
- PRESET-Score内部验证(n=82)AUC 0.845(95%CI 0.76-0.93,p<0.001),外部验证(n=59)AUC 0.70(95%CI 0.56-0.84,p=0.008)。
- 作者认为PRESET-Score预测死亡率远优于既往评分,可能是ARDS患者ECMO置入决策支持的更精确选择。
- 推导队列中位SOFA评分14(12;16),SAPS II 62.5(57;72.8),中位ICU住院17天(范围1-124),死亡率62%。
适用人群与场景
- 推导队列为2010-2015年接受静脉-静脉ECMO的ARDS患者108例,回顾性分析。
- 内部验证队列n=82,外部验证队列n=59,均为接受ECMO治疗的ARDS患者。
研究设计与关键结果
- 研究类型为回顾性分析,推导队列108例,内部验证82例,外部验证59例;人群为接受静脉-静脉ECMO的ARDS患者。
- 推导队列中位SOFA评分14(12;16),SAPS II 62.5(57;72.8),中位ICU住院17天(范围1-124),死亡率62%。
- 四种已有评分中,仅ECMOnet-Score(AUC 0.69)和RESP-Score(AUC 0.64)能区分存活者与死亡者。
- 通过多变量logistic回归确定入ICU时pHa、平均动脉压、乳酸、血小板计数和ECMO前住院时间为独立预测因素,构建PRESET-Score。
- PRESET-Score内部验证AUC 0.845(95%CI 0.76-0.93,p<0.001),外部验证AUC 0.70(95%CI 0.56-0.84,p=0.008),显示优秀区分度。
证据类型、等级与局限
- 证据类型:回顾性分析(推导队列)及内部和外部验证。
- 局限:原文未报告局限性。
对床旁实践的改变
- 在考虑为ARDS患者置入ECMO时,PRESET-Score可能比既往评分提供更精确的死亡率预测,作者认为其是决策支持的更精确选择。
- 使用PRESET-Score需纳入入ICU时pHa、平均动脉压、乳酸、血小板计数和ECMO前住院时间五个变量。
- 既往ECMOnet-Score和RESP-Score也可预测死亡率,但区分度低于PRESET-Score。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Extracorporeal membrane oxygenation (ECMO) is a life-saving therapy in acute respiratory distress syndrome (ARDS) patients but is associated with complications and costs. Here, we validate various scores supposed to predict mortality and develop an optimized categorical model.
METHODS: In a derivation cohort, 108 ARDS patients (2010-2015) on veno-venous ECMO were retrospectively analysed to assess four established risk scores (ECMOnet-Score, RESP-Score, PRESERVE-Score, Roch-Score) for mortality prediction (receiver operating characteristic analysis) and to identify by multivariable logistic regression analysis independent variables for mortality to yield the new PRESET-Score (PREdiction of Survival on ECMO Therapy-Score). This new score was then validated both in independent internal (n = 82) and external (n = 59) cohorts.
RESULTS: The median (25%; 75% quartile) Sequential Organ Failure Assessment score was 14 (12; 16), Simplified Acute Physiology Score II was 62.5 (57; 72.8), median intensive care unit stay was 17 days (range 1-124), and mortality was 62%. Only the ECMOnet-Score (area under curve (AUC) 0.69) and the RESP-Score (AUC 0.64) discriminated survivors and non-survivors. Admission pHa, mean arterial pressure, lactate, platelet concentrations, and pre-ECMO hospital stay were independent predictors of death and were used to build the PRESET-Score. The score's internal (AUC 0.845; 95% CI 0.76-0.93; p < 0.001) and external (AUC 0.70; 95% CI 0.56-0.84; p = 0.008) validation revealed excellent discrimination.
CONCLUSIONS: While our data confirm that both the ECMOnet-Score and the RESP-Score predict mortality in ECMO-treated ARDS patients, we propose a novel model also incorporating extrapulmonary variables, the PRESET-Score. This score predicts mortality much better than previous scores and therefore is a more precise choice for decision support in ARDS patients to be placed on ECMO.
参考来源
- Hilder M, Herbstreit F, Adamzik M, et al. Comparison of mortality prediction models in acute respiratory distress syndrome undergoing extracorporeal membrane oxygenation and development of a novel prediction score: the PREdiction of Survival on ECMO Therapy-Score (PRESET-Score). Crit Care. 2017. PMID: 29233160. doi:10.1186/s13054-017-1888-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。